This review is on the INO-VATE study of inotuzumab ozogamicin compared with standard chemotherapy in patients with relapsed/refractory acute lymphocytic leukaemia.
Independent commentary is provided by Dr. Shaun Fleming, clinical and laboratory haematologist at the Alfred Hospital and a general and malignant haematologist at the Epworth in Richmond.
Please login below to download this issue (PDF)